Table 2: Medications indicated in the study population for

outpatient management of SARS-CoV-2 infection, N = 101.

Drug

Frequency

of

indication

Number

of patients,

(%)

Antibiotics

Azithromycin

Ceftriaxone

Levofloxacin

Clarithromycin

Amikacin, amoxicillin

Cefixime, cephalexin, moxifloxacin,

penicillin, cefotaxime

Erythromycin, lincomycin,

ciprofloxacin, nitrofurantoin,

benzylpenicillin, ampicillin,

ertapenem, clindamycin, norfloxacin,

cefuroxime, cephalothin

 

31

25

15

11

4

2

 

1

 

 

 

 

 

31 (30.7)

25 (24.7)

15 (14.9)

11 (10.9)

7 (6.9)

10 (9.9)

 

8 (7.9)

 

 

 

 

NSAIDS

Paracetamol

Ibuprofen

Aspirin

Metamizole

Naproxen

Meloxicam

Nimesulide, lysine clonixinate,

serratiopeptidase, diclofenac

 

41

20

12

10

3

2

1

 

 

41 (40.6)

20 (19.8)

12 (11.9)

10 (9.9)

3 (2.9)

2 (1.9)

4 (3.9)

 

Airways

Ambroxol

Acetylcysteine

Ipratropium bromide + salbutamol

Salbutamol

Doxofylline, bromhexine,

dextromethorphan, levodropropizine,

theophylline, benzonatate

 

12

5

4

6

1

 

 

 

12 (11.9)

5 (4.9)

4 (3.9)

6 (5.9)

6 (5.9)

 

 

Corticosteroids

Dexamethasone

Prednisone

Budesonide/formoterol, budesonide/

ipratropium bromide

Beclomethasone, betamethasone

Methylprednisolone

Deflazacort/salmeterol/fluticasone

propionate, dexamethasone +

ipratropium bromide/salbutamol,

fluticasone

 

47

14

4

 

3

2

1

 

 

 

 

47 (46.5)

14 (13.8)

8 (7.9)

 

7 (6.9)

2 (1.9)

3 (2.9)

 

 

 

Antihistamines

Loratadine

Chlorphenamine

 

3

2

 

3 (2.9)

2 (1.9)

Anticoagulants

Enoxaparin

Rivaroxaban

Apixaban

Heparin

Dabigatran

Clopidogrel

 

9

4

4

3

1

1

 

9 (8.9)

4 (3.9)

4 (3.9)

3 (2.9)

1 (0.9)

1 (0.9)

Antivirals

Oseltamivir

Lopinavir/ritonavir

Amantadine, acyclovir, elvitegravir/cobicistat/emtricitabine/tenofovir

 

18

2

1

 

 

18 (17.8)

2 (1.9)

3 (2.9)

 

Immunomodulators

Interferon beta, gamma globulin, pidotimod, tocilizumab

 

1

 

 

4 (3.9)

 

NSAIDs = non-steroidal anti-inflammatory drugs.